The Talk Of The Town: Biosimilars Developers React To FDA Streamlining

A Month Of Company Feedback Has Followed The October Guidance

 
• By Dave Wallace
  
The guidance represents a paradigm shift for biosimilars (Shutterstock)

More from Biosimilars

More from Products